Our new discovery research strategy aims at further enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on three pillars:
Four Discovery Research Therapeutic Areas
Build on our strengths in R&D by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.
Focus on highly dynamic research fields such as immune modulation and regenerative medicine which may impact and create synergies among several of our Discovery Research Therapeutic Areas.
Research Beyond Borders
Explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.
Cardiometabolic Diseases Research
Our research and development has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes. Our current research efforts focus on new strategies for the treatment of diabetes, obesity, non-alcoholic Steatohepatitis (NASH), diabetic retinopathy, and chronic kidney disease. Together these therapies complement each other to reduce the risk of cardiovascular mortality and morbidity. Around 300 scientists work in our fully integrated drug discovery centre of excellence for Cardiometabolic research at sites in Biberach, Germany and Ridgefield, CT, USA.
Our Discovery Research focus is on:
Type 2 diabetes
Micro- and macrovascular complications of diabetes – e.g. diabetic retinopathy, diabetic nephropathy, chronic kidney diseases, CV outcomes